Intra-Cellular Therapies Inc. (NASDAQ:ITCI) headquartered in New York, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.intracellulartherapies.com
Earnings Expectation
Intra-Cellular Therapies Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, ITCI is expected to report 2Q20 loss of $ 0.91 per share from revenue of $ 3.03 million. For the full year, analysts anticipate top line of $ 27.71 million, while looking forward to loss of $ 3.46 per share bottom line.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinsons disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
